Krystal Biotech Investor Relations Material
Latest events
Status Update
Krystal Biotech
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Krystal Biotech Inc
Access all reports
Krystal Biotech Inc., known as Krystal Biotech, is a biotechnology firm engaged in the development and commercialization of genetic medicines targeting rare and serious diseases. The company focuses on creating treatments using gene therapy approaches, with a significant emphasis on dermatological conditions. Its product pipeline includes innovative therapies such as bercolagene telserpavec (B-VEC) for dystrophic epidermolysis bullosa, a severe skin disorder, and other treatments targeting conditions like autosomal recessive congenital ichthyosis and aesthetic skin conditions. Utilizing its proprietary skin TARgeted Delivery (STAR-D) platform, Krystal Biotech aims to advance treatments for various skin diseases, leveraging gene therapy's potential to offer long-term solutions. The company is headquartered in Pittsburgh, Pennsylvania, and its shares are listed on the NASDAQ under the ticker symbol KRYS.
Key slides for Krystal Biotech Inc
Study Result
Krystal Biotech Inc
Q3 2024
Krystal Biotech Inc
Latest articles
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
KRYS
Country
🇺🇸 United States